Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial

Romiplostim is approved for the treatment of immune thrombocytopenia (ITP). This study aimed to evaluate the pharmacokinetics, safety, and pharmacodynamics of romiplostim in Chinese patients with ITP. This multicenter, open‐label, dose‐escalation phase I/II trial enrolled ITP patients from 5 centers...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Junyuan, Zheng, Li, Hu, Bei, Zhou, Hu, He, Qing, Liu, Hong, Kawai, Hironori, Yang, Renchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299913/
https://www.ncbi.nlm.nih.gov/pubmed/34921514
http://dx.doi.org/10.1002/cpdd.1059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299913/
https://www.ncbi.nlm.nih.gov/pubmed/34921514
http://dx.doi.org/10.1002/cpdd.1059

Ejemplares similares